Chelsea Therapeutics (Nasdaq:CHTP) is a development stage biopharmaceutical company that seeks to acquire, develop and commercialize innovative products for the treatment of a variety of human diseases that address important unmet medical needs or offer alternatives to current methods of treatment. Chelsea is currently pursuing FDA approval in the U.S. for Northera™ (droxidopa), a novel, late-stage, orally-active therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension in patients with primary autonomic failure.

» learn more about us